At a glance
What is it—and why does it matter?
Pegvisomant is categorized as a GH receptor antagonist, meaning it acts by antagonizing the GH receptor.
Sources for this introduction: [1]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
How does it work?
Target, response, and disposition.
Mechanism
Pegvisomant is described as a GH receptor antagonist, meaning it acts by antagonizing GH receptor signaling.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Pegvisomant, a GH receptor antagonist,”
Current treatment landscape of acromegaly. · Abstract
pubmed:41965092:dfc997f88f44:dfc997f88f44
Mechanism
Pegvisomant is categorized as a GH receptor antagonist, meaning it acts by antagonizing the GH receptor.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Biochemical control rates were comparable among long-acting injectable somatostatin receptor ligands (SRLs), including lanreotide autogel (LAN-ATG), octreotide long-acting release (OCT-LAR), pasireotide, the GH receptor antagonist pegvisomant, oral octreotide (O-OCT), octreotide subcutaneous depot (SC-OCT-D), and the once-daily oral SRL paltusotine.”
Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis. · RESULTS
pubmed:41773305:97833c31f346:97833c31f346
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, identity, interaction, regulatory, safety
- 24 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (19), assurance_score_below_0.72 (5), current_regulatory_source_required (4), extraction_ambiguity (24), high_risk_requires_regulatory_or_two_independent_sources (5), no_direct_support (24)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis. ↗
pubmed · published 2026-05-19 · retrieved 2026-08-28T12:18:09Z
- Current treatment landscape of acromegaly. ↗
pubmed · published 2026-06-04 · retrieved 2026-08-24T17:38:00Z
Publication history and provenance
Version 3 · Automated assessment · 2026-08-28T12:18:09Z
fdac71a9e266ba46880132c06b0f8a534ed3f54b3f3b59cc1a01066baaf4861d